From: The role of ubiquitin-specific peptidases in cancer progression
Gene symbol | Cellular location | Substrate | Function and remarks in cancer | Inhibitor | References |
---|---|---|---|---|---|
USP1 | N |
FANCD2 PCNA | DNA repair; Oncogene | Pimozideb, ML323, GW7647, C527, 6-Amino-pyrimidines, SJB2-043, SJB3-019A, PR619 | [92, 110,111,112,113,114] |
USP2 | C, N | Fatty acid synthase, cyclin D1, MDM2 and 4 | Fas/p53, NF-κB, c-Myc; Oncogene | NSC632839, AM146, RA-9, RA-14, 2-cyano-pyrimidines and -triazinesb, ML364, PR619 | [18, 31, 44, 114,115,116,117,118,119,120,121,122] |
USP3 | N | H2A, H2B | DDR, Oncogene | [123,124,125] | |
USP4 | C, N | TRAF2, TRAF6 | TGFβ, NFκB, Wnt, p53; Oncogene | Vialinin A, PR619 | [81, 114, 126,127,128] |
USP5 | L, V, Ca | p53, DDR, Oncogene | G9, Vialinin A, WP1130, EOAI3402143, AM146, RA-9, RA-14, PR619 | [49, 93, 106, 114, 118, 127, 129,130,131,132] | |
USP6 | Golgi, C | NFκB activation; Oncogene or Suppressor | [133] | ||
USP7 | N, C, PML body | HDM2, p53, H2B, TP53, MDM2 & 4, FOXO4, PTEN | Oncogene | P5091, Cpd14, P22077, HBX41108, HBX 19818, HBX 28258, NSC632839, WO2013030218, P0050429, W02013030218, PR619 | [114, 117, 121, 134,135,136,137,138,139,140,141,142,143,144,145,146] |
USP8 | C, N | NRDP1, RNF128, STAM2 | Oncogene | HBX90397, HBX41108, AM146, RA-9, RA-14, Ethyloxyimino-9H-indeno[1,2-b] pyrazine-2,3-dicarbonitrile, PR619 | [95, 114, 118, 147,148,149,150] |
USP9X | C, E, L, V | β-catenin, epsins, AF-6, SMAD2 | TGFβ, Mcl-1, ERG, AGS-3, ITCH, Wnt, Notch; Oncogene or suppressor | G9, WP1130, PR619 | [106, 107, 114, 130,131,132, 151,152,153,154] |
USP9Y | C | Spematogenesis | [155] | ||
USP10 | C, N | TP53, SNX3, CFTR | c-Myc, p53; Oncogene or suppressor | P22077, HBX19818, Spautin-1, PR619 | [32, 56, 114, 156,157,158] |
USP11 | N, C | BRCA2, NFκBIA | DDR, NFκB; Oncogene | Mitoxantroneb | [70, 104, 159,160,161] |
USP12 | Androgen receptor | Oncogene | GW7647 | [92, 162,163,164] | |
USP13 | L, V, C, Na | MCL1, BECN1, USP10 | Spautin-1 | [157, 165,166,167] | |
USP14 | C, PM | Wnt; Oncogene | VLX1570b, IU1, WP1130, b-AP15, AC17, Auranofinb, Tricyclic heterocyclics, Azepan-4-ones, PR619 | [106, 114, 132, 168,169,170,171,172,173,174,175] | |
USP15 | C, N | RBX1, SMAD1, 2, 3 & 7 | NFκB, Wnt; Oncogene | PR619 | [114, 176,177,178,179] |
USP16 | N | H2A | Chromosome condensation; Oncogene | PR619 | [114, 180,181,182,183] |
USP17 | SUDS3 | Oncogene | [184,185,186] | ||
USP18 | C, N | TAK1, TAB1, PTEN | JAK-STAT, NFκB; Oncogene | [187, 188] | |
USP19 | ER | RNF123 | ERAD | PR619 | [114, 189,190,191] |
USP20 | C, N, | DIO2, ADRB2, TRAF6, Tax | Thyroid hormone, hypoxia, NFκB; Oncogene | PR619 | [114, 192, 193] |
USP21 | C, N | H2A, RIPK1, DDX58, GATA3, IL33 | NFκB, NEDD8; Oncogene | [72, 194,195,196,197,198] | |
USP22 | N | H2A | c-Myc; Oncogene | PR619 | [114, 199,200,201,202] |
USP24 | C | TP53, DDB2, MCL1, Bax, p300, E2F4, securin, βTrCP |
Cell growth repressor; Metastasis promoter; Overexpression in M2 macrophages | G9, PR619 | [23, 57, 75, 106, 114, 130, 131, 203] |
USP25 | C, N | DDX58 | ERAD; Oncogene | [204,205,206] | |
USP26 | N (testis) | AR | Spermatogenesis | [207,208,209] | |
USP27X | BCL2L11 | tumor suppressor | [58, 210] | ||
USP28 | N |
CLSPN, c-MYC; Oncogene or suppressor | PR619 | [114, 211, 212] | |
USP29 | Na | p53 pathway; Oncogene | [213, 214] | ||
USP30 | M | MFN1, MFN2, DRP1, Parkin | Hepatocarcinogenesis | [215,216,217] | |
USP31 | N, C | Inhibition of NFκB | [218] | ||
USP32 | PM, Golgi | Oncogene | [219] | ||
USP33 | C, N, centrosome | HIF1-α DIO2, ADRB2, CCP110, ARRB | Tumor suppressor | [192, 220,221,222,223] | |
USP34 | C, N, PM, Extracellular | AXIN1, AXIN2, | Activation of Wnt; Inhibition of EMT and cancer stemness | [102, 224] | |
USP35 | Na | ABIN-2, Aurora B | Tumor suppressor through inactivating NFκB | [225, 226] | |
USP36 | N | c-Myc | Oncogene | ||
USP37 | N, | c-Myc | Increase in DNA damage repair; Oncogene | ||
USP38 | C, N, GAa | ||||
USP39 | N | Oncogene | |||
USP40 | C, N, PM | ||||
USP41 | Na | ||||
USP42 | Na | TP53 | p53; Oncogene | [53, 227, 228] | |
USP43 | Na | H2BK120 | Tumor suppressor | ||
USP44 | N | CDC20, EZH2 | Oncogene | [229] | |
USP45 | C, N | ||||
USP46 | L, Va | Oncogene | Pimozideb | [113] | |
USP47 | C | POLB | Oncogene | P5091, Cpd14, P22077, PR619 | [114, 136, 137, 139, 230] |
USP48 | C, N | Gli1 | Oncogene | PR619 | [114] |
USP49 | N | H2B | Tumor suppressor | [231] | |
USP50 | Na | G2/M checkpoint | [232] | ||
USP51 | Na | ||||
PAN2 | C, N | ||||
USP53 | Golgi, Na | ||||
USP54 | Ma | Oncogene | |||
USPL1 | N, Cajal body | ||||
DUB3 | H2AX |
G2/M checkpoint; Cancer associated | [233, 234] | ||
CYLD | C, N, PM | TRAF2/6, NEMO, TRPA1, Tak1, Lck, Bcl3, Dvl, DDX58, K63polyUb-RIPK1, K63polyUβ-IKBKG | NFκB and JNK-STAT; Familial tumor suppressor | [68, 235,236,237,238,239] |